Akero Net Receivables vs Total Stockholder Equity Analysis
AKRO Stock | USD 19.48 1.02 4.98% |
Akero Therapeutics financial indicator trend analysis is way more than just evaluating Akero Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akero Therapeutics is a good investment. Please check the relationship between Akero Therapeutics Net Receivables and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.
Net Receivables vs Total Stockholder Equity
Net Receivables vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akero Therapeutics Net Receivables account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Akero Therapeutics' Net Receivables and Total Stockholder Equity is 0.79. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Akero Therapeutics, assuming nothing else is changed. The correlation between historical values of Akero Therapeutics' Net Receivables and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Akero Therapeutics are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Net Receivables i.e., Akero Therapeutics' Net Receivables and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.79 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Net Receivables
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Akero Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akero Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.As of the 23rd of May 2024, Selling General Administrative is likely to drop to about 29 K. In addition to that, Issuance Of Capital Stock is likely to drop to about 180.6 M
Akero Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Akero Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Akero Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 138.1M | 273.3M | 195.5M | 356.6M | 580.3M | 609.3M | |
Other Current Liab | 8.4M | 9.4M | 18.2M | 10.8M | 11.8M | 9.4M | |
Total Current Liabilities | 9.4M | 13.1M | 25.1M | 19.1M | 19.1M | 13.9M | |
Total Stockholder Equity | 128.7M | 258.7M | 169.1M | 326.6M | 535.3M | 562.1M | |
Net Tangible Assets | 128.7M | 258.7M | 169.1M | 326.6M | 375.5M | 394.3M | |
Net Debt | (136.4M) | (185.4M) | (149.0M) | (238.8M) | (208.2M) | (218.6M) | |
Retained Earnings | (130.3M) | (209.5M) | (310.3M) | (422.3M) | (574.1M) | (545.4M) | |
Accounts Payable | 947K | 3.4M | 6.7M | 8.0M | 7.0M | 4.3M | |
Cash | 136.4M | 187.2M | 150.5M | 249.8M | 234.2M | 162.6M | |
Non Current Assets Total | 69K | 2.0M | 2.0M | 1.4M | 20.3M | 21.3M | |
Non Currrent Assets Other | 29K | 161K | 417K | 108K | (1.0) | (0.95) | |
Other Assets | 69K | 201K | 417K | 108K | 1.0 | 0.95 | |
Cash And Short Term Investments | 136.4M | 268.4M | 188.3M | 351.4M | 550.0M | 577.5M | |
Common Stock Shares Outstanding | 15.1M | 31.5M | 34.8M | 39.0M | 52.6M | 34.6M | |
Short Term Investments | 71.6M | 81.1M | 37.8M | 101.7M | 315.8M | 331.6M | |
Liabilities And Stockholders Equity | 138.1M | 273.3M | 195.5M | 356.6M | 580.3M | 609.3M | |
Non Current Liabilities Total | 23K | 1.5M | 1.3M | 10.9M | 25.8M | 19.4M | |
Other Current Assets | 1.6M | 3.0M | 5.3M | 3.7M | 10.0M | 10.4M | |
Other Stockholder Equity | 120.9M | 468.2M | 479.4M | 748.9M | 1.1B | 1.2B | |
Total Liab | 9.4M | 14.6M | 26.4M | 30.0M | 45.0M | 29.5M | |
Net Invested Capital | 128.7M | 258.7M | 169.1M | 336.1M | 560.3M | 588.3M | |
Total Current Assets | 138.0M | 271.3M | 193.6M | 355.2M | 560.0M | 588.0M | |
Accumulated Other Comprehensive Income | (6K) | (3K) | (27K) | 37K | 270K | 283.5K | |
Net Working Capital | 128.7M | 258.2M | 168.5M | 336.1M | 540.8M | 567.9M | |
Capital Surpluse | 259.0M | 468.2M | 479.4M | 748.9M | 861.2M | 438.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Akero Stock analysis
When running Akero Therapeutics' price analysis, check to measure Akero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akero Therapeutics is operating at the current time. Most of Akero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akero Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akero Therapeutics' price. Additionally, you may evaluate how the addition of Akero Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Akero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.24) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.